Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Abasaglar® (insulin glargin): Byte från Insulin Degludec

Abasaglar har inte studerats hos patienter som tidigare behandats med insulin degludek. Vid övergång från insulin degludek till Abasaglar kan därför en annan dos av Abasaglar samt annan medicin behövas.

Detailed information

Abasaglar has not been studied in patients previously on IDeg.

Based on patient-level meta-analyses that were performed on 7 phase 3a trials that compared IDeg with IGlar (Table 1), a transition from IDeg to Abasaglar may be made on a unit-to-unit basis. The dose of Abasaglar  may require up titration for

  • basal-bolus-treated T1DM patients, and

  • insulin-naive T2DM patients.1

Table 1. Daily Mean Dose of Insulin Glargine and Insulin Degludec at End of Trial1

Category

IGlar

IDeg

Dose Difference

P Value

T1DMB/B

0.77 units/kg
(n=314)

0.68 units/kg
(n=634)

12%

<.0001

T2DMinsulin-naive

0.43 units/kg
(n=625)

0.39 units/kg
(n=1267)

10%

.0004

T2DMB/B

1.18 units/kg
(n=249)

1.22 units/kg
(n=749)

0%

NS

Abbreviations: IDeg = insulin degludec; IGlar = insulin glargine; NS = not significant; T1DMB/B = basal-bolus-treated patients with type 1 diabetes mellitus; T2DMB/B = basal-bolus-treated patients with type 2 diabetes mellitus; T2DMinsulin-naïve = insulin-naive patients with type 2 diabetes mellitus.

Changes in Insulin Regimen

Patients may be predisposed to hypoglycemia or hyperglycemia by changes in insulin

  • strength

  • manufacturer

  • type, or

  • method of administration.2

Insulin treatment changes should be made

  • under close medical supervision, and

  • with increased frequency of BG monitoring.2

The doses and timing of concurrent rapid- or short-acting insulins or other concomitant antihyperglycemic medications may need to be adjusted.2

References

1. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435-446. http://dx.doi.org/10.1007/s13300-014-0076-9

2. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

BG = blood glucose

IDeg = insulin degludec

IGlar = insulin glargine

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2020 M01 07


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss